These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 8211211)

  • 41. Platelet crossmatch testing for donor selection.
    Slichter SJ
    Prog Clin Biol Res; 1982; 88():153-64. PubMed ID: 7100207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alloimmunization following platelet transfusions in patients with acute nonlymphocytic leukemia.
    Nozaki H; Shimizu M; Komatsuda M; Watanabe K; Nagao T; Arimori S
    Tokai J Exp Clin Med; 1986 Aug; 11(3):201-4. PubMed ID: 3475819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia.
    Ganti AK; Landmark JD; Kessinger A; Smith LM; Tarantolo SR
    In Vivo; 2006; 20(4):559-63. PubMed ID: 16900790
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review.
    Vassallo RR; Fung M; Rebulla P; Duquesnoy R; Saw CL; Slichter SJ; Tanael S; Shehata N;
    Transfusion; 2014 Apr; 54(4):1180-91. PubMed ID: 24032995
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transfusion strategy: use of HLA-matched platelet transfusions for alloimmunized patients.
    Menitove JE; Duquesnoy RJ
    Am J Med Technol; 1981 Feb; 47(2):114-20. PubMed ID: 7223758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Scintigraphy with indium-111-labeled homologous (donor) platelets in the platelet transfusion refractory bone marrow transplant patient.
    Hammersmith SM; Jacobson AF; Mankoff DA
    J Nucl Med; 1997 Jul; 38(7):1135-8. PubMed ID: 9225806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
    Antun AG; Gleason S; Arellano M; Langston AA; McLemore ML; Gaddh M; el Rassi F; Bernal-Mizrachi L; Galipeau J; Heffner LT; Winton EF; Khoury HJ
    Cancer; 2013 Nov; 119(21):3784-7. PubMed ID: 23921838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The effect of HLA alloimmunization and other factors on the effectiveness of thrombocyte concentrates].
    Pittrová H; Koza V; Cepelák V; Bufková D
    Cas Lek Cesk; 1990 Jun; 129(24):751-3. PubMed ID: 2393882
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Platelet transfusions.
    Kelton JG; Blajchman MA
    Can Med Assoc J; 1979 Nov; 121(10):1353-8. PubMed ID: 391376
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension.
    Claas FH; Smeenk RJ; Schmidt R; van Steenbrugge GJ; Eernisse JG
    Exp Hematol; 1981 Jan; 9(1):84-9. PubMed ID: 7238645
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of HLA-C matching in histocompatible platelet transfusion therapy of alloimmunized thrombocytopenic patients.
    Duquesnoy RJ; Filip DJ; Tomasulo PA; Aster RH
    Transplant Proc; 1977 Dec; 9(4):1827-8. PubMed ID: 601843
    [No Abstract]   [Full Text] [Related]  

  • 52. Strategies for managing refractoriness to platelet transfusions.
    Dan ME; Schiffer CA
    Curr Hematol Rep; 2003 Mar; 2(2):158-64. PubMed ID: 12901147
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Complement as an Immune Barrier in Platelet Transfusion Refractoriness.
    Meinke S; Karlström C; Höglund P
    Transfus Med Rev; 2019 Oct; 33(4):231-235. PubMed ID: 31679761
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New strategies for the optimal use of platelet transfusions.
    Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
    Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
    Trial to Reduce Alloimmunization to Platelets Study Group
    N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Managing of platelet transfusion refractoriness of haematological malignancies. Experience IPC-EFSAM].
    Dettori I; Ladaique P
    Transfus Clin Biol; 2014 Nov; 21(4-5):207-9. PubMed ID: 25267204
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
    Saris A; Pavenski K
    Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical factors influencing the efficacy of pooled platelet transfusions.
    Bishop JF; McGrath K; Wolf MM; Matthews JP; De Luise T; Holdsworth R; Yuen K; Veale M; Whiteside MG; Cooper IA
    Blood; 1988 Feb; 71(2):383-7. PubMed ID: 3337903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases.
    Klingemann HG; Self S; Banaji M; Deeg HJ; Doney K; Slichter SJ; Thomas ED; Storb R
    Br J Haematol; 1987 May; 66(1):115-21. PubMed ID: 3593647
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
    Panch SR; Guo L; Vassallo R
    Blood Rev; 2023 Nov; 62():101135. PubMed ID: 37805287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.